THE GLOBAL MULTI-OMICS SOLUTION FOR PRECISION ONCOLOGY

2023 - A new, exciting future 

Indivumed evolves into Indivumed Therapeutics after the acquisition of Indivumed Services GmbH and its CRO service offerings by Crown Bioscience. Leveraging its global clinical cooperation with leading cancer clinics in Europe, Americas, and Asia and its unique multi-omics database Indivumed Therapeutics will drive data analytics-driven drug and diagnostic development.

Read more

2022 - On our Mission

We remain firmly focused on our mission: to support precision oncology. In January, the IndivuType project receives 4.3 million euros in EU funding from the ERDF structural fund. It’s another important boost for us to continue pursuing our goal beyond mere profit maximization.

2021 - Unraveling

Our groundbreaking data analytics platform sees the light of day: nRavel^®. Utilizing cutting-edge AI technology and the world’s most comprehensive multi-omics cancer database, the platform helps to literally unravel the complexity of cancer.

2018 - We Have a Type

Supported by the European Fund for Strategic Investments (EFSI), the European Investment Bank (EIB) provides us with a EUR 40 million loan. Thanks to this and additional private funding, just one year later we are able to launch IndivuType, the world’s first real multi-omics knowledge and discovery solution.

2017 - Networking

Our clinical network reaches an important milestone: as the first partner in Asia, the Indian Institute of Technology in Madras joins our ever-growing global network, closely followed in 2018 by A*STAR’s Institute of Molecular and Cell Biology (IMCB) in Singapore. To date, the network consists of more than 100 permanent clinical partners, including leading hospitals, clinics, and oncology practices in Europe, North America, and Asia.

2008 - Drawing Blood

Together with scientists led by Professor Bert Vogelstein from Johns Hopkins University, we found Inostics GmbH to elaborate a new system of cancer gene diagnostics from blood. A few years later, the team is recognized by the AACR for its pioneering work in using cancer mutations as biomarkers in the context of liquid biopsies – a dramatic technological advancement in detecting cancer that defined a new field in oncology. Inostics is sold in 2013 to allow Indivumed to pursue other areas of research.

2005 - The Visionary

The jury of Deutscher Gründerpreis (German Founders Award) honors Hartmut Juhl with the award in the “Visionary” category. The prestigious award celebrates outstanding entrepreneurial achievements and recognizes personalities who turn visions into ventures.

2004 - New World

We expand overseas, and in April 2004 found Indivumed Inc. The American subsidiary is initially limited to sales and the development of the US clinical network. Today, the company has long had its own laboratory operations for customers in the United States.

2002 - Indi… what?

As early as September 2001, Dr. Hartmut Juhl starts Indivumed GmbH. Shortly afterwards, Dr. Carsten Zornig, Dr. Peter Layer, and Frank Oertel join as cofounders. Despite – or perhaps because of – the name, which might be difficult to pronounce at first, investors are quickly found. With them and the first five employees, operations begin April 5, 2002. Soon after, Indivumed is awarded the Hamburger Gründerpreis for being the best start-up company in Hamburg.